thalidomide has been researched along with 17p11.2 Monosomy in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biran, N | 1 |
| Jagannath, S | 1 |
| Chari, A | 1 |
| Strati, P | 1 |
| Keating, MJ | 1 |
| O'Brien, SM | 1 |
| Ferrajoli, A | 1 |
| Burger, J | 1 |
| Faderl, S | 1 |
| Tambaro, FP | 1 |
| Jain, N | 1 |
| Wierda, WG | 1 |
| Sun, C | 1 |
| Wiestner, A | 1 |
| Lee, J | 1 |
| Smith, D | 1 |
| Rabin, N | 1 |
| Tobias, J | 1 |
| Yong, K | 1 |
2 reviews available for thalidomide and 17p11.2 Monosomy
| Article | Year |
|---|---|
Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Chr | 2013 |
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, | 2015 |
2 other studies available for thalidomide and 17p11.2 Monosomy
| Article | Year |
|---|---|
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Topics: Autografts; Bortezomib; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 17; Consolida | 2016 |